Volume 15, Issue 1 ( March 2023 2023)                   Iranian Journal of Blood and Cancer 2023, 15(1): 53-59 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammadpour A H, Ghaffarzadegan K, Raygani R, Izanloo A, Mehri S, Jannati M et al . Serum visfatin level as a prognostic marker in colorectal cancer patients: A retrospective cohort study. Iranian Journal of Blood and Cancer 2023; 15 (1) :53-59
URL: http://ijbc.ir/article-1-1361-en.html
Serum visfatin level as a prognostic marker in colorectal cancer patients: A retrospective cohort study
Amir Hooshang Mohammadpour1 , Kamran Ghaffarzadegan2 , Ranna Raygani1 , Azra Izanloo2 , Soghra Mehri3 , Mahdi Jannati1 , Sepideh Elyasi * 4
1- Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
2- Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran
3- Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
4- Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran , elyasis@mums.ac.ir
Abstract:   (740 Views)

Background: Colorectal cancer is the third common cancer in women and the fourth one among men, worldwide. Identifying prognostic factors are among the current challenges in cancer management. There are some evidence that visfatin, an adipocyte-secreted peptide, plays a significant role in cancer progression, proliferation, angiogenesis, metastasis, and drug resistance. In this study, we examined the serum concentration of visfatin and its impact on colorectal cancer prognosis.
Methods: Sixty-nine colorectal patients who had been followed up for two years at Razavi Hospital, Mashhad, Iran were evaluated. Information regarding the patients’ cancer status, including primary tumor location, tumor size, histology, tumor differentiation, stage of TNM, metastasis or lymphatic invasion, treatment options over the past two years, as well as the disease status, including recurrences and survival, was collected. An ELISA kit was used to measure serum visfatin concentrations and the relationship between serum visfatin concentrations and the prognosis of colorectal cancer was examined using SPSS software.
Results: Visfatin played a small role in death, metastasis, and recurrence of colorectal cancer. Additionally, Cox regression analysis revealed no significant relationship between death, metastasis and recurrence rate and visfatin concentration (p>0.05). Additionally, no significant difference in visfatin concentration was found between two genders.
Conclusion: The results of this study showed that according to survival analysis and Cox regression, there was no significant association between serum concentration of visfatin and death, metastasis, or recurrence in colorectal cancer.So, visfatin does not seem a good biomarker for colorectal cancer prognosis prediction. Further studies are recommended.

Keywords: Visfatin, Colorectal cancer, Prognostic marker, Survival
Full-Text [PDF 289 kb]   (402 Downloads)    
Subject: Gastroentrology
Received: 2023/01/10 | Accepted: 2023/02/24 | Published: 2023/03/30
References
1. Sheikhpour R. Visfatin and its role in breast cancer. Middle East Journal of Cancer. 2017;8(4):171-7.
2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-91. [DOI:10.1136/gutjnl-2015-310912]
3. Kantor ED, Lampe JW, Peters U, Vaughan TL, White E. Long-chain omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer. Nutrition and cancer. 2014;66(4):716-27. [DOI:10.1080/01635581.2013.804101]
4. Pacheco-Pérez LA, Ruíz-González KJ, de-la-Torre-Gómez ACG, Guevara-Valtier MC, Rodríguez-Puente LA, Gutiérrez-Valverde JM. Environmental factors and awareness of colorectal cancer in people at familial risk. Revista latino-americana de enfermagem. 2019;27. [DOI:10.1590/1518-8345.3082.3195]
5. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. Journal of obesity. 2013;2013:291546. [DOI:10.1155/2013/291546]
6. Słomian G, Świętochowska E, Nowak G, Pawlas K, Żelazko A, Nowak P. Chemotherapy and plasma adipokines level in patients with colorectal cancer. Advances in Hygiene & Experimental Medicine/Postepy Higieny i Medycyny Doswiadczalnej. 2017;71. [DOI:10.5604/01.3001.0010.3813]
7. Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: a role for adipokines. European urology. 2007;52(1):46-53. [DOI:10.1016/j.eururo.2007.03.054]
8. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. The Journal of clinical endocrinology and metabolism. 2004;89(6):2548-56. [DOI:10.1210/jc.2004-0395]
9. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54(10):2911-6. [DOI:10.2337/diabetes.54.10.2911]
10. Ackerman SE, Blackburn OA, Marchildon F, Cohen P. Insights into the Link Between Obesity and Cancer. Current obesity reports. 2017;6(2):195-203. [DOI:10.1007/s13679-017-0263-x]
11. Hung AC, Lo S, Hou MF, Lee YC, Tsai CH, Chen YY, Liu W, Su YH, Lo YH, Wang CH, Wu SC, Hsieh YC, Hu SC, Tai MH, Wang YM, Yuan SS. Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22(17):4478-90. [DOI:10.1158/1078-0432.CCR-15-2704]
12. Neubauer K, Misa IB, Diakowska D, Kapturkiewicz B, Gamian A, Krzystek-Korpacka M. Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1beta, and anemia. BioMed research international. 2015;2015:523930. [DOI:10.1155/2015/523930]
13. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49(4):744-7. [DOI:10.1007/s00125-006-0173-z]
14. Garten A, Petzold S, Barnikol-Oettler A, Korner A, Thasler WE, Kratzsch J, Kiess W, Gebhardt R. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun. 2010;391(1):376-81. [DOI:10.1016/j.bbrc.2009.11.066]
15. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science (New York, NY). 2005;307(5708):426-30. [DOI:10.1126/science.1097243]
16. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Molecular and cellular biology. 1994;14(2):1431-7. https://doi.org/10.1128/MCB.14.2.1431 [DOI:10.1128/mcb.14.2.1431-1437.1994]
17. Kim JG, Kim EO, Jeong BR, Min YJ, Park JW, Kim ES, Namgoong IS, Kim YI, Lee BJ. Visfatin stimulates proliferation of MCF-7 human breast cancer cells. Molecules and cells. 2010;30(4):341-5. [DOI:10.1007/s10059-010-0124-x]
18. Lin T-C. The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis. Cancer management and research. 2019;11:3481. [DOI:10.2147/CMAR.S199597]
19. Fazeli MS, Keramati MR, Rahimi A, Kazemeini A, Banoei MM, Dashti H, Fazeli AR. Visfatin level in patients with colorectal adenoma. Medical journal of the Islamic Republic of Iran. 2016;30:320.
20. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T, Shimada Y. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer science. 2010;101(5):1286-91. [DOI:10.1111/j.1349-7006.2010.01518.x]
21. Lee Y-C, Yang Y-H, Su J-H, Chang H-L, Hou M-F, Yuan S-SFJCE, Biomarkers P. High visfatin expression in breast cancer tissue is associated with poor survival. 2011;20(9):1892-901. [DOI:10.1158/1055-9965.EPI-11-0399]
22. Tian W, Zhu Y, Wang Y, Teng F, Zhang H, Liu G, Ma X, Sun D, Rohan T, Xue FJGo. Visfatin, a potential biomarker and prognostic factor for endometrial cancer. 2013;129(3):505-12. [DOI:10.1016/j.ygyno.2013.02.022]
23. Ghaemmaghami S, Mohaddes SM, Hedayati M, Mohammadi MG, Dehbashi G. Resistin and visfatin expression in HCT-116 colorectal cancer cell line. International journal of molecular and cellular medicine. 2013;2(3):143. [DOI:10.5812/scimetr.16718]
24. Neubauer K, Bednarz Misa I, Diakowska D, Kapturkiewicz B, Gamian A, Krzystek-Korpacka M. Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1β, and anemia. BioMed research international. 2015;2015. [DOI:10.1155/2015/523930]
25. Lv X, Zhang L, Zhu Y, Said HM, Shi J, Xu G. Regulative effect of Nampt on tumor progression and cell viability in human colorectal cancer. Journal of Cancer. 2015;6(9):849. [DOI:10.7150/jca.12341]
26. Lu G-W, Wang Q-J, Xia M-M, Qian J. Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients. Peptides. 2014;58:60-4. [DOI:10.1016/j.peptides.2014.05.016]
27. Yan X, Zhao J, Zhang R. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1). Cancer chemotherapy and pharmacology. 2017;80(2):395-403. [DOI:10.1007/s00280-017-3365-y]
28. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends in molecular medicine. 2005;11(8):344-7. [DOI:10.1016/j.molmed.2005.06.010]
29. Teplan V, Senolt L, Hulejova H, Stollova M, Gurlich R. Early changes in serum visfatin after abdominal surgery: a new pro-inflammatory marker in diagnosis? Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2015;159(3):489-96. [DOI:10.5507/bp.2014.012]
30. Yang G, Fan W, Luo B, Xu Z, Wang P, Tang S, Xu P, Yu M. Circulating resistin levels and risk of colorectal cancer: a meta-analysis. BioMed research international. 2016;2016. [DOI:10.1155/2016/7367485]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb